SCP
EW icon

Sandhill Capital Partners’s Edwards Lifesciences EW Stock Holding History

Sandhill Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Hold
15,822
– – 0.12% 57
2026
Q1 		$1.27M Sell
15,822
-750
-5% -$61.8K 0.11% 54
2025
Q4 		$1.41M Hold
16,572
– – 0.1% 56
2025
Q3 		$1.29M Sell
16,572
-1,500
-8% -$117K 0.09% 58
2025
Q2 		$1.41M Hold
18,072
– – 0.1% 53
2025
Q1 		$1.31M Sell
18,072
-2,400
-12% -$172K 0.11% 55
2024
Q4 		$1.52M Hold
20,472
– – 0.12% 56
2024
Q3 		$1.35M Hold
20,472
– – 0.1% 57
2024
Q2 		$1.89M Hold
20,472
– – 0.15% 55
2024
Q1 		$1.96M Sell
20,472
-4,500
-18% -$378K 0.16% 52
2023
Q4 		$1.9M Buy
24,972
+900
+4% +$62.6K 0.16% 52
2023
Q3 		$1.67M Hold
24,072
– – 0.16% 57
2023
Q2 		$2.27M Hold
24,072
– – 0.21% 53
2023
Q1 		$1.99M Hold
24,072
– – 0.19% 55
2022
Q4 		$1.8M Hold
24,072
– – 0.19% 57
2022
Q3 		$1.99M Sell
24,072
-12,000
-33% -$1.15M 0.23% 57
2022
Q2 		$3.43M Buy
36,072
+10,000
+38% +$1.04M 0.37% 55
2022
Q1 		$3.07M Sell
26,072
-1,000
-4% -$112K 0.26% 35
2021
Q4 		$3.51M Sell
27,072
-1,000
-4% -$117K 0.27% 34
2021
Q3 		$3.18M Sell
28,072
-1,000
-3% -$114K 0.25% 33
2021
Q2 		$3.01M Sell
29,072
-940
-3% -$88.6K 0.23% 34
2021
Q1 		$2.51M Buy
30,012
+12
+0% +$1.01K 0.21% 36
2020
Q4 		$2.74M Sell
30,000
-7
-0% -$581 0.25% 37
2020
Q3 		$2.4M Buy
30,007
+7
+0% +$546 0.24% 40
2020
Q2 		$2.07M Hold
30,000
– – 0.24% 38
2020
Q1 		$1.89M Sell
30,000
-120
-0.4% -$8.65K 0.25% 41
2019
Q4 		$2.34M Buy
30,120
+120
+0.4% +$9.37K 0.26% 36
2019
Q3 		$2.2M Buy
+30,000
New +$2.11M 0.27% 35
2013
Q4 		– Sell
-659,892
Closed -$7.66M – 84
2013
Q3 		$7.66M Buy
659,892
+19,134
+3% +$224K 3.44% 16
2013
Q2 		$7.18M Buy
+640,758
New +$7.58M 3.55% 13

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Sandhill Capital Partners's EW Position: Q2 2026 in Review

Sandhill Capital Partners held its Edwards Lifesciences (EW) position steady in Q2 2026 at 15,822 shares worth $1.43M. The position accounts for 0.12% of the portfolio, ranked #57.

Sandhill Capital Partners first reported a position in EW in Q2 2013 and has held it in 30 quarters since. The position peaked at $7.66M in Q3 2013. 1,336 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Sandhill Capital Partners held 15,822 shares of Edwards Lifesciences worth $1.43M as of Q2 2026.
  • Sandhill Capital Partners left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.12% of Sandhill Capital Partners's portfolio in Q2 2026, its #57 holding.
  • Sandhill Capital Partners first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 30 quarters since.
  • Sandhill Capital Partners's Edwards Lifesciences position peaked at $7.66M in Q3 2013.
  • 1,336 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Sandhill Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.